Please ensure Javascript is enabled for purposes of website accessibility

Why Pacira Pharmaceuticals, Inc. Shares Are Spiking 21% Today

By Todd Campbell - Aug 4, 2016 at 1:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Better-than-expected sales and profits are igniting investor optimism.

Image source: Pacira Pharmaceuticals.

What: Shares of Pacira Pharmaceuticals (PCRX 2.65%) are rallying 19.7% at 1:00 p.m. EDT after the company reported second-quarter financials that outpaced industry watchers' estimates.

So what: Pacira Pharmaceuticals generates 96% of its revenue from Exparel, a surgical pain medication, and in the second quarter, rising demand for Exparel resulted in sales of  $69.6 million, up 17.7% year over year, and earnings per share (EPS) of $0.19, which was $0.16 ahead of analyst expectations. 

"The second quarter marked another period of double-digit, year-over-year revenue growth as we advanced multiple initiatives to support Exparel in the latter half of this year and into 2017," said Pacira CEO and Chairman Dave Stack. "Our aggressive investments in patient outreach and clinical development, as well as commercial and educational programs, are progressing as planned. For the rest of this year, we look forward to continuing the strong progress we've made with the Phase 4 randomized controlled trials in strategic orthopedic surgeries, Phase 3 nerve block studies, enhanced recovery protocols in soft tissue procedures and data presentations on bundled payments. We also anticipate increasing our public relations and advocacy efforts to bring attention to addressing the opioid epidemic by providing an alternative to opioids in the acute postsurgical setting, where epidemic often starts."

The strong results suggest that doctors are increasingly turning to Exparel, rather than opioids, to relieve patient pain following procedures, and given that the market for opioid pain relief is worth billions of dollars annually, the company's runway for growth could be long. 

Worldwide, pain drugs are the second-biggest class of drugs -- about 300 million prescriptions written last year were worth an estimated $24 billion. 

Now what: Pacira is positioning Exparel as a better-than-opioid option and studies that confirm its ability to provide pain relief in multiple settings could lead to label expansions that significantly expand the drug's addressable market. For example, the company plans to launch Exparel for use in oral surgery, such as wisdom teeth procedures, in the coming months. 

Overall, Pacira's double-digit growth and profitability make it an intriguing stock for biotech investors to own, especially given that doctors are increasingly looking for non-opioid pain solutions in the wake of rising opioid abuse. Pacira's management is guiding for sales of at least $270 million, up from $249 million in 2015, and the various revenue tailwinds could lead to even greater sales next year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pacira BioSciences, Inc. Stock Quote
Pacira BioSciences, Inc.
PCRX
$63.04 (2.65%) $1.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
327%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.